Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

en versus placebo, and a larger effect in the patients not receiving chronic inhaled antibiotics. The effect of inhaled antibiotics was largely attributable to the use of inhaled aminoglycosides. In the intent to treat population, there was a 3% difference in the relative change from baseline in %-predicted FEV1 between the ataluren and placebo groups at Week 48 (-2.5% change on ataluren vs. -5.5% change on placebo; p=0.124). An analysis of the relative change from baseline in %-predicted FEV1 across all post-baseline study visits demonstrated an average difference between ataluren and placebo of 2.5% (-1.8% average change on ataluren vs. -4.3% average change on placebo; p= 0.0478).

The study was stratified for age, baseline FEV1, and the use of chronic inhaled antibiotics. A statistically significant effect (p=0.0072) was seen between treatment and use of inhaled antibiotics at baseline, indicating that inhaled antibiotics was a significant confounder of the overall results. A substantial treatment effect was seen in the patients not receiving chronic inhaled antibiotics at baseline; the Week 48 difference between the ataluren and placebo arms in FEV1 was 6.7% (-0.2% change on ataluren vs. -6.9% change on placebo).

The secondary endpoint, the rate of pulmonary exacerbations (ie, the number of pulmonary exacerbations in 48 weeks) also showed a positive trend in favor of ataluren, with the rate in the ataluren group being 23% lower than the placebo group (p=.0992). In the patients not receiving chronic inhaled antibiotics, the pulmonary exacerbation rate in the ataluren group was 43% lower than the rate in the placebo group. These results show a consistent treatment effect of ataluren on both pulmonary function and exacerbation rates. Mean relative change in %-predicted FEV1 (ITT population)Ataluren vs. PlaceboDifferencep-valueAll patients at Week 48
ataluren n=116; placebo n=116

3.0%

0.124All patients – averag
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. 23, ... International plc (NASDAQ: ENDP ) (TSX: ENL), ... ) announced today that they have submitted a New ... the U.S. Food and Drug Administration (FDA).  Buprenorphine HCl ... pain severe enough to require daily, around-the-clock, long-term opioid ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Therapeutics, Inc. (Nasdaq: NLTX ), a company focused ... disease, today announced its third quarter financial results for 2010. ... 30, 2010, Nile reported a net loss of approximately $1.8 ... of approximately $2.0 million, or $0.08 per share, during the ...
... N.J., Nov. 12, 2010 Neurologix, Inc. (OTC Bulletin ... company developing innovative gene therapies for the brain and ... for the three and nine months ended September 30, ... potential of NLX-P101, our Parkinson,s disease gene therapy product, ...
Cached Medicine Technology:Nile Therapeutics Reports 2010 Third Quarter Financial Results 2Nile Therapeutics Reports 2010 Third Quarter Financial Results 3Nile Therapeutics Reports 2010 Third Quarter Financial Results 4Neurologix Reports Third Quarter 2010 Financial Results 2Neurologix Reports Third Quarter 2010 Financial Results 3Neurologix Reports Third Quarter 2010 Financial Results 4Neurologix Reports Third Quarter 2010 Financial Results 5Neurologix Reports Third Quarter 2010 Financial Results 6Neurologix Reports Third Quarter 2010 Financial Results 7Neurologix Reports Third Quarter 2010 Financial Results 8
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the ... the business has introduced its new collection of 2015 ... , The new prom outfits are guaranteed to contain ... They are specially designed for 2015. Anyone who wants ... visit its website before Jan. 26, 2015, the deadline ...
(Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
(Date:12/25/2014)... 25, 2014 Residents at ... recently showed their generous spirit by providing holiday ... County Parenting Network- Grandparents Raising Grandchildren program. , ... around the largest Christmas tree on the campus ... by residents of the Abernethy Village Association (AVA). ...
(Date:12/25/2014)... December 25, 2014 Parker & Sons, ... customer service and affordable quality regarding heating, cooling and ... recognition in 2014 by the “Queen of Clean” for ... earned an impressive reputation over the years for providing ... wide range of contractor services for both homeowners and ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife clinics ... smiling little faces this holiday that might not have ... donations was given to the various charities as well ... through the year. Some of the charities chosen for ... Shrine's Children's Hospitals, Toys for Tots and Crisis Nurseries, ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife Donates Over 700 Toys This Year 2
... Sayre Area School District in Bradford County today became ... H1N1 influenza vaccine to its student population, the Department ... reminded all parents that immunizations play a significant role ... disproportionately affecting school-aged children, with almost two-thirds of all ...
... into diseases and treatments, experts say , FRIDAY, Oct. ... detailed map of the human epigenome, gaining greater understanding ... past, we,ve been limited to viewing small snippets of ... Genomic Analysis Laboratory at the Salk Institute for Biological ...
... RATON, Fla., Oct. 16 Although stem cells sounds ... for quite some time. In today,s advanced medical ... orthopedic conditions including osteoarthritis of the hip knee and ... rotator cuff tears, and various back conditions including ...
... physicians will be using electronic prescribing and other health ... million federal grant secured by U.S. Senator Patrick Leahy. ... Technology Leaders, Inc. (VITL), will provide incentives to physicians ... In June, Vermont was cited by Surescripts as the ...
... DALLAS, Oct. 16 John Killian, Chairman of Parent ... the United States focused on finding a cure for Duchenne ... that the 5th Annual Sam,s Family Fun Day ... 10am to 2pm on Flagpole Hill at White Rock Lake. ...
... The Avon Foundation for Women is marking Breast ... celebrations, and tributes. Throughout October, the Foundation will call ... save lives, and raise millions of dollars for the ... the sale of fundraising products, Avon Walks for Breast ...
Cached Medicine News:Health News:Pennsylvania Department of Health Announces First School to Begin Administering H1N1 Vaccine to Students 2Health News:Scientists Provide First Map of Complete Human Epigenome 2Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 2Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 4Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 5Health News:Sam's Day Celebrates 5 Year Anniversary; Local Family Event Will Benefit Largest U.S. Non-Profit Fighting Duchenne Muscular Dystrophy 2Health News:Sam's Day Celebrates 5 Year Anniversary; Local Family Event Will Benefit Largest U.S. Non-Profit Fighting Duchenne Muscular Dystrophy 3Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 2Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 3
Suitable for mild to moderate ACL and/or PCL, MCL and LCL instabilities, this neoprene brace with extended hinge bars is an ideal intermediate-level product that can be used in sporting activities. C...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Provides comfortable compression, support and immobilization for the knee...
Dynamic brace that provides a low load, prolonged stretch to the connective tissue around the joint using an adjustment hinge with a built-in tension spring...
Medicine Products: